跳到正文
原文
Nature Medicine· Hari Venkatesh Pai·· 7 天前AI 评分15

KRAS靶向治疗或迎来疫苗新前沿

Vaccines could be a new frontier in KRAS targeting

AI 导读

研究表明,疫苗可能成为KRAS靶向治疗的新领域。作者指出,尽管目前尚无针对KRAS的获批疗法,但疫苗在这一领域展现出潜力,值得进一步探索。

正文

Competing interests

S.S. has received speaker and/or advisory board fees from Servier, AstraZeneca, Revolution Medicines, Viatris, Pfizer, Bristol Myers Squibb (BMS) and Novartis; and support for conference attendance from Merck. S.S. has received institutional research funding from Revolution Medicines, Genentech, Arcus, BMS, AstraZeneca and Amgen. S.S. holds a US patent relating to pancreatic cancer diagnostic technology and owns shares in Astron Health. The other authors declare no competing interests.

来源:Nature Medicine · nature.com